Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04390308
Other study ID # 2004-ABU-005-LM
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date November 23, 2023
Est. completion date July 31, 2024

Study information

Verified date November 2023
Source ART Fertility Clinics LLC
Contact Barbara Lawrenz, PhD
Phone +97126528000
Email shieryl.digma@artfertilityclinics.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Premature ovarian failure (POI) is a loss of normal function before age 40, leading to infertility and hypoestrogenism. About 1% of women younger than 40 years old and 0.1% before 30 are affected. Most patients already had impaired or complete loss of fecundity when diagnosed. Hence, the treatment of POI is particularly tough. Currently, no optimal regimen exists to ameliorate ovarian function.


Description:

In women, the non-growing population of follicles that comprise the ovarian reserve is determined at birth and serves as the reservoir for future fertility. This reserve of dormant, primordial follicles and the mechanisms controlling their selective activation which constitute the committing step into folliculogenesis are essential for determining fertility outcomes in women. While POI is sometimes called premature menopause, it is not identical with menopause. Women with POI may still have occasional irregular periods and may even occasionally achieve a pregnancy. Symptoms of POI include irregular menses or amenorrhea, infertility, hypoestrogenic symptoms and decreased libido. POI may be caused by chromosomal defects such as mosaic Turner's syndrome, exposure to toxins (chemotherapy or radiation), autoimmunity, genetic factors (FMR1) and other unknown factors. Recently, new promising approaches have emerged for infertility treatment in patients with POI, which are based on arousing the still available primordial follicle pool. It is supposed that these techniques activate dormant primordial follicles using a combination of mechanical signaling and biochemical factors. The hypothesis that mild local ovarian injury, such as ovarian puncture, which is a usual procedure in an IVF center with minimal side effects, might exert a similar favorable effect in women with POI arouses our curiosity. Different groups have published case series of ovarian procedures, injecting substances in the ovaries (A-PRP) or ovarian biopsies / scratch in infertile patients with low ovarian reserve (LOR) or/and patients with POF. However, those studies were underpowered, including not enough number of cases, with variable inclusion criteria and reporting results with very low scientific evidence. Furthermore, the mechanical effect of injecting the ovary should be taken into consideration during the evaluation of these patients, yet it might improve the ovarian function as well. There are no previous randomized controlled trials considering a procedure as ovarian puncture, which is easier and accessible at any fertility center.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 70
Est. completion date July 31, 2024
Est. primary completion date June 30, 2024
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria: - Signed and dated informed consent - Women 40 years of age and younger with documented primary ovarian insufficiency (12). - Normal Karyotype - BMI </= 35 kg/m2 - Oligo/amenorrhea for at least 4 months - FSH > 25 IU/mL - AMH </= 0,1 ng/ml - No evidence of follicles > 4mm - Must have two ovaries of approximately equal volume. - Willingness to undergo further fertility treatment, including IVF if there is evidence of response - A transvaginal scan including Doppler for arteria ovarica will be performed previously to the surgical procedure. Exclusion Criteria: - Premature ovarian failure due to a genetic origin, such as Turner's Syndrome or chromosomal abnormality. - Oncological diseases (specially, skeletal system and blood). - Autoimmune diseases, for example, lupus erythematosus, etc. - Previous treatments including radiotherapy or chemotherapy. - Other conditions not suitable for surgical procedures and/or anesthesia. - Anticoagulant or antiaggregant treatment. - Acute and chronic infectious diseases. - Active substance abuse or dependence. - Major Mental health disorder.

Study Design


Intervention

Procedure:
Ovarian puncture
Egg collection
Other:
Hormonal blood Test
AMH (ng/ml), FSH (IU/mL), E2(pg/mL), P4(ng/mL), LH (IU/mL)
Diagnostic Test:
Transvaginal ultrasound
Doppler of arteria ovarica. Resistance index

Locations

Country Name City State
United Arab Emirates ART Fertility Clinics LLC Abu Dhabi

Sponsors (1)

Lead Sponsor Collaborator
ART Fertility Clinics LLC

Country where clinical trial is conducted

United Arab Emirates, 

References & Publications (11)

European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI; Webber L, Davies M, Anderson R, Bartlett J, Braat D, Cartwright B, Cifkova R, de Muinck Keizer-Schrama S, Hogervorst E, Janse F, Liao L, Vlaisavljevic V, Zillikens C, V — View Citation

Ford EA, Beckett EL, Roman SD, McLaughlin EA, Sutherland JM. Advances in human primordial follicle activation and premature ovarian insufficiency. Reproduction. 2020 Jan;159(1):R15-R29. doi: 10.1530/REP-19-0201. — View Citation

Gurtner GC, Werner S, Barrandon Y, Longaker MT. Wound repair and regeneration. Nature. 2008 May 15;453(7193):314-21. doi: 10.1038/nature07039. — View Citation

Kawamura K, Kawamura N, Hsueh AJ. Activation of dormant follicles: a new treatment for premature ovarian failure? Curr Opin Obstet Gynecol. 2016 Jun;28(3):217-22. doi: 10.1097/GCO.0000000000000268. — View Citation

Lacci KM, Dardik A. Platelet-rich plasma: support for its use in wound healing. Yale J Biol Med. 2010 Mar;83(1):1-9. — View Citation

Nurden AT. Platelets, inflammation and tissue regeneration. Thromb Haemost. 2011 May;105 Suppl 1:S13-33. doi: 10.1160/THS10-11-0720. Epub 2011 Apr 11. — View Citation

Sfakianoudis K, Simopoulou M, Nitsos N, Rapani A, Pantou A, Vaxevanoglou T, Kokkali G, Koutsilieris M, Pantos K. A Case Series on Platelet-Rich Plasma Revolutionary Management of Poor Responder Patients. Gynecol Obstet Invest. 2019;84(1):99-106. doi: 10.1 — View Citation

Sills ES, Li X, Rickers NS, Wood SH, Palermo GD. Metabolic and neurobehavioral response following intraovarian administration of autologous activated platelet rich plasma: First qualitative data. Neuro Endocrinol Lett. 2019 Jan;39(6):427-433. — View Citation

Sills ES, Rickers NS, Li X, Palermo GD. First data on in vitro fertilization and blastocyst formation after intraovarian injection of calcium gluconate-activated autologous platelet rich plasma. Gynecol Endocrinol. 2018 Sep;34(9):756-760. doi: 10.1080/095 — View Citation

Sills ES, Rickers NS, Svid CS, Rickers JM, Wood SH. Normalized Ploidy Following 20 Consecutive Blastocysts with Chromosomal Error: Healthy 46, XY Pregnancy with IVF after Intraovarian Injection of Autologous Enriched Platelet-derived Growth Factors. Int J — View Citation

Zhang X, Han T, Yan L, Jiao X, Qin Y, Chen ZJ. Resumption of Ovarian Function After Ovarian Biopsy/Scratch in Patients With Premature Ovarian Insufficiency. Reprod Sci. 2019 Feb;26(2):207-213. doi: 10.1177/1933719118818906. Epub 2018 Dec 12. — View Citation

* Note: There are 11 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Other Clinical pregnancy by blood test pregnancy (yes or no) defined by a ßhCG test of > 15IU 12 weeks
Other Implantation rate (%) defined by the number of gestational sacs/number of embryos transferred 4 weeks
Other Clinical pregnancy by ultrasound defined by the ultrasonographic visualization of one or more gestational sacs, including ectopic pregnancies 12 weeks
Primary Follicle growth above 4 mm One or more follicles evaluated by transvaginal ultrasound. Defined by number of follicles growing, quantitative variable. 1 day
Primary Anti-Müllerian hormone evaluation after intervention. Anti-Müllerian hormone evaluation after intervention. 1 day
Primary Follicle-stimulating hormone evaluation after intervention. Follicle-stimulating hormone evaluation after intervention. 1 day
Primary Luteinizing hormone evaluation after intervention. Luteinizing hormone evaluation after intervention. 1 day
Primary Estradiol hormone evaluation after intervention. Estradiol hormone evaluation after intervention. 1 day
Primary Progesterone hormone evaluation after intervention. Progesterone hormone evaluation after intervention. 1 day
Primary Spontaneous menstruation. Spontaneous menstruation. 1 day
Primary Arteria ovarica doppler results. Arteria ovarica doppler results. Resistance index. 1 day
Secondary Number of follicles Number of follicles 1 day
Secondary Number of oocytes retrieved Number of oocytes retrieved 1 day
Secondary Fertilization rate percentage of 2PN embryos per oocyte injected 1 day
Secondary Blastulation rate percentage of blastocysts per 2PN embryos 1 day
Secondary Aneuploidy rate percentage of aneuploid blastocysts per total blastocyst biopsied 1 day
See also
  Status Clinical Trial Phase
Recruiting NCT05969574 - Is Decreased Ovarian Reserve Related to an Increased Number of Previous Early Miscarriages?
Recruiting NCT05358483 - PROspective Study of Mothers' and Infants' Social and Epidemiologic Determinants of Health
Recruiting NCT05969795 - Comparison of Live Birth Rate in Natural Cycle Single Euploid FET Versus Without Luteal Phase Support Phase 1
Recruiting NCT06051201 - Innovation for Small-scale Experiments: ReceptIVFity Test N/A
Completed NCT03177538 - Corifollitropin Alfa Combined With Menotropin Versus Follitropin and Lutropin Alfa in Expected Suboptimal Responders Phase 4
Completed NCT03638856 - Comparing Effectiveness of Oral Misoprostal for Cervical Priming in Hysteroscopy N/A
Completed NCT04052464 - The Study of the Implantation Window From Endometrial Biopsy With Gene Expression Methods
Withdrawn NCT04753736 - Immunophenotypage of RIF and RM Patients and Intrauterine Administration of PBMC N/A
Completed NCT03349905 - Deferred Versus Fresh Embryo Transfers N/A
Completed NCT05076981 - Progesterone Levels During Ovulation and Luteal Phase
Completed NCT04096027 - Cabergoline Before or After Oocyte Collection for Follicular Resolution Phase 4
Recruiting NCT05980091 - Optimal Timing of Euploid Day 6 Blastocyst Transfer in Frozen HRT Cycles, Day 6 or Day 7 of Progesterone Administration. Phase 1
Terminated NCT01933633 - Improved Fertility After Exercise in Overweight/Obese Women N/A
Completed NCT01202656 - Effect of Colony Stimulating Factor on Implantation and Pregnancy Rates Following IVF (in Vitro Fertilization) Phase 1/Phase 2
Terminated NCT01202643 - Effect of Colony Stimulating Factor on Poor Endometrial Development During IVF Phase 1/Phase 2
Completed NCT01408615 - A Post Marketing Observational Study of the Safety and Efficacy of Elonva (Corifollitropin Alfa) in General Practice (P08165)
Enrolling by invitation NCT05698550 - The Role of Erzhi Tiangui Formula in Expected POR Women Undergoing IVF-ET Phase 3
Not yet recruiting NCT03910582 - Personalized FET in RIF Patients With Displaced Dating N/A
Completed NCT05440019 - Evaluation of the Safety and Usability of the M3T Fertigo System and Its Calibration
Completed NCT05130125 - Retrospective Cohort Observational Study to Evaluate the Effectiveness and Safety of Fresh or Frozen Embryo Transfer